Gilead Sciences Inc. said it aims to launch Sovaldi, its blockbuster hepatitis C drug, in India by June while expanding the reach of a generic licensing agreement with Indian drugmakers to include an investigational combination pill. The pill, which combines sofosbuvir, the chemical name for Sovaldi, with GS-5816, a compound in advanced clinical trials in the U.S., could treat six genotypes of hepatitis C if approved by regulators. Gilead will ask India's health ministry to waive clinical trials and expedite approval for the compound, which eliminates the need for costly genotype tests, Gregg Alton, an executive vice president at the Foster City, California-based company, said in a phone interview.